Unknown

Dataset Information

0

Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate.

ABSTRACT: Metoprolol is a selective ?-1 adrenergic receptor blocker that undergoes extensive metabolism by the polymorphic enzyme cytochrome P450 2D6 (CYP2D6). Our objective was to investigate the influence of CYP2D6 polymorphisms on the efficacy and tolerability of metoprolol tartrate. Two hundred and eighty-one participants with uncomplicated hypertension received 50?mg of metoprolol twice daily followed by response-guided titration to 100?mg twice daily. Phenotypes were assigned based on results of CYP2D6 genotyping and copy number variation assays. Clinical response to metoprolol and adverse effect rates were analyzed in relation to CYP2D6 phenotypes using appropriate statistical tests. Heart rate response differed significantly by CYP2D6 phenotype (P < 0.0001), with poor and intermediate metabolizers showing greater reduction. However, blood pressure response and adverse effect rates were not significantly different by CYP2D6 phenotype. Other than a significant difference in heart rate response, CYP2D6 polymorphisms were not determinants of variability in metoprolol response or tolerability.

SUBMITTER: Hamadeh IS 

PROVIDER: S-EPMC4111800 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate.

Hamadeh I S IS   Langaee T Y TY   Dwivedi R R   Garcia S S   Burkley B M BM   Skaar T C TC   Chapman A B AB   Gums J G JG   Turner S T ST   Gong Y Y   Cooper-DeHoff R M RM   Johnson J A JA  

Clinical pharmacology and therapeutics 20140317 2

Metoprolol is a selective β-1 adrenergic receptor blocker that undergoes extensive metabolism by the polymorphic enzyme cytochrome P450 2D6 (CYP2D6). Our objective was to investigate the influence of CYP2D6 polymorphisms on the efficacy and tolerability of metoprolol tartrate. Two hundred and eighty-one participants with uncomplicated hypertension received 50 mg of metoprolol twice daily followed by response-guided titration to 100 mg twice daily. Phenotypes were assigned based on results of CYP  ...[more]

Similar Datasets

Unknown CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis.
| S-EPMC7256128 | biostudies-literature
Unknown A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.
| S-EPMC3818912 | biostudies-literature
Unknown Cytochrome P450 Enzymes Involved in Metoprolol Metabolism and Use of Metoprolol as a CYP2D6 Phenotyping Probe Drug.
| S-EPMC6066528 | biostudies-literature
Unknown The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine.
| S-EPMC6255988 | biostudies-literature
Unknown Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores.
| S-EPMC7762806 | biostudies-literature
Unknown Advancing USP compendial methods for fixed dose combinations: A case study of metoprolol tartrate and hydrochlorothiazide tablets.
| S-EPMC6460378 | biostudies-literature
Unknown Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions.
| S-EPMC7763912 | biostudies-literature
Unknown Functional characterization of CYP2D6 enhancer polymorphisms.
| S-EPMC4381757 | biostudies-literature
Unknown Mexazolam: clinical efficacy and tolerability in the treatment of anxiety.
| S-EPMC4381915 | biostudies-literature
Unknown Lomitapide: a review of its clinical use, efficacy, and tolerability.
| S-EPMC6615460 | biostudies-literature